ABOS - Acumen Pharmaceuticals, Inc. News

Acumen Pharmaceuticals Exercises Option For Development, Production, Commercialization Of Two Candid

JCR Pharmaceuticals Co., Ltd. (TSE 4552; JCR), a global specialty biopharmaceutical company dedicate

businesswire.com

JCR Pharmaceuticals Announces That Acumen Pharmaceuticals Has Exercised its Exclusive Option to Deve

HYOGO, Japan--(BUSINESS WIRE)--JCR Pharmaceuticals Co., Ltd. (TSE 4552; JCR), a global specialty bio

Acumen Pharmaceuticals Nominates Two Development Candidates In Its Enhanced Brain Delivery Program F

ACU301 and ACU401 were nominated in the EBD program as part of the exercise of Acumen's option u

Acumen Pharmaceuticals Announces Nomination of Two Enhanced Brain Delivery™ (EBD™) Development Candi

ACU301 and ACU401 were nominated in the EBD program as part of the exercise of Acumen's option under

Acumen's Late-2026 Sabirnetug Readout Is A Viable Bet

Acumen Pharmaceuticals is a clinical-stage Alzheimer's biotech built around sabirnetug. I believe 20

Acumen Pharmaceuticals, Inc. (ABOS) Presents at Bank of America Global Healthcare Conference 2026 Tr

Acumen Pharmaceuticals, Inc. (ABOS) Q1 2026 Earnings Call Transcript

marketbeat.com

Acumen Pharmaceuticals Q1 Earnings Call Highlights

Acumen Pharmaceuticals NASDAQ: ABOS said its Phase 2 ALTITUDE-AD trial of sabirnetug remains on trac

Acumen Pharmaceuticals Reports Q1 2026 Results: Full Earnings Call Transcript

Earnings Scheduled For May 12, 2026

Acumen Pharmaceuticals Q1 EPS $(0.33) Beats $(0.36) Estimate

Acumen Pharmaceuticals (NASDAQ:ABOS) reported quarterly losses of $(0.33) per share which beat the a

Acumen Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Highlights

NEWTON, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen

Acumen Pharmaceuticals to Participate in the Bank of America Securities 2026 Health Care Conference

NEWTON, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clini

Acumen Pharmaceuticals to Report First Quarter Financial Results on May 12, 2026

NEWTON, Mass., May 05, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen

zacks.com

Acumen Pharmaceuticals (ABOS) Loses 33.6% in 4 Weeks, Here's Why a Trend Reversal May be Around the

The heavy selling pressure might have exhausted for Acumen Pharmaceuticals (ABOS) as it is technical

zacks.com

Is Acumen Pharmaceuticals (ABOS) Stock Outpacing Its Medical Peers This Year?

Here is how Acumen Pharmaceuticals, Inc. (ABOS) and ADC Therapeutics SA (ADCT) have performed compar

Analysts Set Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Target Price at $7.00

Shares of Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS - Get Free Report) have been assigned a consens

12 Health Care Stocks Moving In Friday's Pre-Market Session

Acumen Pharmaceuticals, Inc. (ABOS) Q4 2025 Earnings Call Transcript

Acumen Pharmaceuticals Files Prospectus To Resell Up To 10,833,331 Shares From March 16, 2026 Privat

ACUMEN PHARMACEUTICALS, INC.Up to 10,833,331 shares of Common Stock This prospectus relates to th

BTIG Reiterates Buy on Acumen Pharmaceuticals, Maintains $8 Price Target

BTIG analyst Thomas Shrader reiterates Acumen Pharmaceuticals (NASDAQ:ABOS) with a Buy and mainta

Acumen Pharmaceuticals Q4 EPS $(0.41) Beats $(0.43) Estimate

Acumen Pharmaceuticals (NASDAQ:ABOS) reported quarterly losses of $(0.41) per share which beat the a

Earnings Scheduled For March 26, 2026

Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2025 and Business H

NEWTON, Mass., March 26, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acu

Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2025 Financial Results on March 26, 202

NEWTON, Mass., March 19, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acum

Acumen Pharma Announces New Research Findings At International Conference On Alzheimer's And Parkins

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS), a clinical-stage biopharmaceutical company developing no

Market-Moving News for March 16th

NBIS: 17% | Nebius Announced 5-Year $12B AI Infrastructure Agreement With Meta To Provide Dedicated

Acumen Pharmaceuticals Announces Private Placement Of ~$35.75M At $3.30/Share

Proceeds from the financing are expected to primarily support Acumen's Enhanced Brain Delivery (

Acumen Pharmaceuticals Announces $35.75 Million Private Placement to Advance Potential Best-in-Class

NEWTON, Mass., March 16, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acu

Acumen Pharmaceuticals to Participate in the Stifel 2026 Virtual CNS Forum

NEWTON, Mass., March 10, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a cli

Acumen Shares New Alzheimer's Drug Data At Global Brain Disease Conference

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS), a clinical-stage biopharmaceutical company developing a

12 Health Care Stocks Moving In Friday's After-Market Session

Baker Hughes To Rally More Than 15%? Here Are 10 Top Analyst Forecasts For Tuesday

BTIG Maintains Buy on Acumen Pharmaceuticals, Raises Price Target to $7

BTIG analyst Thomas Shrader maintains Acumen Pharmaceuticals (NASDAQ:ABOS) with a Buy and raises

12 Health Care Stocks Moving In Monday's Intraday Session

12 Health Care Stocks Moving In Monday's Pre-Market Session

Daniel Joseph Oconnell Sells 12,941 Shares of Acumen Pharmaceuticals (NASDAQ:ABOS) Stock

Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS - Get Free Report) CEO Daniel Joseph Oconnell sold 12,941

Matt Zuga Sells 6,888 Shares of Acumen Pharmaceuticals (NASDAQ:ABOS) Stock

Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS - Get Free Report) CFO Matt Zuga sold 6,888 shares of Acu

Daniel Joseph Oconnell Sells 8,143 Shares of Acumen Pharmaceuticals (NASDAQ:ABOS) Stock

Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS - Get Free Report) CEO Daniel Joseph Oconnell sold 8,143

Acumen And JCR Pharma Collaborative Study Shows Improved Brain Distribution of AβO-Targeting Antibod

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS), a clinical-stage biopharmaceutical company developing a

B of A Securities Maintains Buy on Acumen Pharmaceuticals, Lowers Price Target to $8

B of A Securities analyst Geoff Meacham maintains Acumen Pharmaceuticals (NASDAQ:ABOS) with a Buy

Earnings Scheduled For November 12, 2025

Preview: Acumen Pharmaceuticals's Earnings

12 Health Care Stocks Moving In Thursday's Intraday Session

Gainers PepGen (NASDAQ: PEPG) stock rose 114.3% to $5.7 during Thursday's regular session. The

B of A Securities Maintains Buy on Acumen Pharmaceuticals, Lowers Price Target to $9

B of A Securities analyst Geoff Meacham maintains Acumen Pharmaceuticals (NASDAQ:ABOS) with a Buy

Acumen Pharmaceuticals Q2 EPS $(0.68) Misses $(0.52) Estimate

Acumen Pharmaceuticals (NASDAQ:ABOS) reported quarterly losses of $(0.68) per share which missed the

Earnings Scheduled For August 12, 2025

Acumen Pharmaceuticals's Earnings: A Preview

Watching Acumen Pharmaceuticals; Shares Move Higher, Traders Circulate Daily Mail Article Titled "Sc

https://www.dailymail.co.uk/health/article-14954333/dementia-jab-breakthrough-Alzheimers.html